This study it to evaluate the usability of the WearLinq eWave patch in a general adult population.
Once eligibility is determined, participants will receive and apply the WearLinq patch for 7 consecutive days (or until an endpoint is met). A subset of subjects will be asked to participate in an Extended Use Cohort (30 days).
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
500
This device is a wearable multi-channel ECG monitoring device for continuous cardiac rhythm tracking.
ABio Clinical Research Partners
New London, North Carolina, United States
Wear Duration
Days of use until one of the following is reached: patch no longer adheres, signal loss, voluntary removal, or 7 days is achieved
Time frame: 7 Days
Adverse Events
Incidences of self-reported adverse events for the duration of the study
Time frame: 7 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.